Glatiramer
| العنوان: | Glatiramer |
|---|---|
| المؤلفون: | Babaesfahani A; Ross University, Kern Medical Center, Bajaj T; University of Chicago |
| المصدر: | 2022 Jan. |
| المصدر: | In: StatPearls |
| نوع المنشور: | Study Guide |
| اللغة: | English |
| بيانات الدورية: | Publisher: StatPearls Publishing Cited Medium: Internet |
| أسماء مطبوعة: | Treasure Island (FL) : StatPearls Publishing |
| مستخلص: | Glatiramer is an immunomodulator used in the treatment and management of multiple sclerosis. Its mechanism is not clearly understood, but it appears to work by altering the immune processes responsible for MS. This activity reviews the indications, contraindications, mechanism of action, adverse events, and other key elements of glatiramer therapy and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes for patients with multiple sclerosis. (Copyright © 2022, StatPearls Publishing LLC.) |
| References: | Weinstock-Guttman B, Nair KV, Glajch JL, Ganguly TC, Kantor D. Two decades of glatiramer acetate: From initial discovery to the current development of generics. J Neurol Sci. 2017 May 15;376:255-259. (PMID: 28431621) Caporro M, Disanto G, Gobbi C, Zecca C. Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Patient Prefer Adherence. 2014;8:1123-34. (PMID: PMC414493325170258) McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015 May;29(5):425-32. (PMID: 25906331) Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M, PreCISe study group Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 31;374(9700):1503-11. (PMID: 19815268) Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler. 2001 Aug;7(4):209-19. (PMID: 11548979) Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven-Kreitman R, Tarcik N, Teitelbaum D. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol. 2001 Apr 02;115(1-2):152-60. (PMID: 11282165) Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, Kolbeck R, Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999 Mar 01;189(5):865-70. (PMID: PMC219294210049950) Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M, Buccheister A, Hu J, Latif Z, Tselis A, Lisak R. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2005 Dec;11(6):646-51. (PMID: 16320723) Tselis A, Khan O, Lisak RP. Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2007 Apr;3(2):259-67. (PMID: PMC265462719300558) Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, GALA Study Group Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013 Jun;73(6):705-13. (PMID: 23686821) Drugs and Lactation Database (LactMed) [Internet] National Library of Medicine (US); Bethesda (MD): 2022. Aug 15, Glatiramer. (PMID: 0) Farez MF, Correale J, Armstrong MJ, Rae-Grant A, Gloss D, Donley D, Holler-Managan Y, Kachuck NJ, Jeffery D, Beilman M, Gronseth G, Michelson D, Lee E, Cox J, Getchius T, Sejvar J, Narayanaswami P. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019 Sep 24;93(13):584-594. (PMID: 31462584) |
| تواريخ الأحداث: | Date Created: 20220411 |
| رمز التحديث: | 20240629 |
| PMID: | 31082051 |
| Book AN: | NBK541007 |
| قاعدة البيانات: | MEDLINE |
| الوصف غير متاح. |